• Traders who were banking on some kind of hugely positive announcement (more consequential than the M402 news) in conjunction with the quarterly results might be inclined to sell today.
• There could be some selling stemming from MNTA’s guidance for continued quarterly losses until Copaxone is approved, although this should not have been a surprise to anyone who follows the company closely.
If anyone has a better explanation, please post.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”